Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CENPE | Q02224 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776494 | 0.87 | CENPE (0.54) | MEN1KMT2AAKR1C3CENPENOS2 | |
| SCHEMBL4776493 | 0.87 | CENPE (0.54) | MEN1KMT2AAKR1C3CENPENOS2 | |
| SCHEMBL4776495 | 0.87 | CENPE (0.54) | MEN1KMT2AAKR1C3CENPENOS2 | |
| SCHEMBL4776505 | 0.67 | MMP9 (0.52) | PPARG | |
| SCHEMBL4778789 | 0.65 | LTA4H (0.55) | — | |
| SCHEMBL566342 | 0.65 | CSNK2A1 (0.55) | MEN1KMT2ACSNK2A1 | |
| SCHEMBL4321455 | 0.64 | CSNK2A1 (0.63) | PPARGMEN1KMT2ACSNK2A1 | |
| SCHEMBL3704073 | 0.64 | CTSC (0.54) | — | |
| SCHEMBL3704071 | 0.64 | CTSC (0.54) | — | |
| SCHEMBL10976287 | 0.64 | CSNK2A1 (0.62) | MEN1KMT2AS1PR1KDM4ECSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | claimed |
| EP-1942732-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| WO-2007056143-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219192-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | PPARG 2756/4885MEN1 1302/4885KMT2A 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.